This project is a phase III, multi-center, open-label, safety, tolerability and efficacy study of Adderall-XR in the treatment of adolescents aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD).

Thomas Lock, MD

Mark L. Wolraich, MD

Shire Pharmaceuticals

2003-2005